Targeting BRAF in BRAF-mutant melanoma is highly effective, but most patients develop resistance. HSP90 has been implicated and identified as a therapeutic target. Ultimately, early-stage clinical investigation will be necessary to provide proof of principle of this approach and if appropriate randomized trials to confirm promising findings. Clin Cancer Res; 24(22); 5496–8. ©2018 AACR.
See related article by Eroglu et al., p. 5516
https://ift.tt/2qMD3UM
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου
Σημείωση: Μόνο ένα μέλος αυτού του ιστολογίου μπορεί να αναρτήσει σχόλιο.